Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 7,019 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MATCHING PLACEBO Clear all
Completed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
Interventions
Emricasan (5 mg), Emricasan (50 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
83
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

NCT00718861
View directory record Official record
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

NCT03385369
View directory record Official record
Conditions
Safety, Healthy Subjects
Interventions
MEDI0382, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

NCT01232283
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast, Placebo, Topical or Phototherapy Therapy
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
19
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

NCT01691846
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
aleglitazar+metformin, placebo+metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

NCT00645788
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ciprofloxacin (Cipro Inhale, BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

NCT04572841
View directory record Official record
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Interventions
SAR441344, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy

NCT00388297
View directory record Official record
Conditions
Subclinical Hypothyroidism, Hypothyroxinemia, Pregnancy
Interventions
Levothyroxine, Placebo for Levothyroxine
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
1,203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

NCT02546960
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V (4 : 4 : 4 : 4), ExPEC4V (4 : 4 : 4 : 8), ExPEC4V (8 : 8 : 8 : 8), ExPEC4V (8 : 8 : 8 : 16), ExPEC4V (16 : 16 : 16 : 16), Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596
View directory record Official record
Conditions
Cocaine Dependency
Interventions
CPP-115, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride

NCT00424762
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT01034462
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Dothan, Alabama • Highlands Ranch, Colorado • Boca Raton, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 26, 2026, 7:29 AM EDT
Terminated Phase 4 Interventional

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

NCT04938388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Semaglutide Pill, Fresh organic vegetables
Drug · Dietary Supplement
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03703882
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 26, 2026, 7:29 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 2 Interventional

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

NCT00904462
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Lidoderm, Placebo patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
24
States / cities
Birmingham, Alabama • Hueytown, Alabama • Tallassee, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

NCT03891862
View directory record Official record
Conditions
Tardive Dyskinesia (TD)
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 26, 2026, 7:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN and TMG (Euexia), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

NCT02606461
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 26, 2026, 7:29 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 26, 2026, 7:29 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers

NCT07700368
View directory record Official record
Conditions
Healthy Adult
Interventions
L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl)
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 26, 2026, 7:29 AM EDT
Terminated Phase 2 Interventional Results available

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

NCT02216097
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 26, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

NCT05070546
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection Prevention
Interventions
Ad26.RSV.preF-based Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 26, 2026, 7:29 AM EDT